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Pancreatic Endocrine Tumors: A Report on a Patient Treated with 
Sorafenib
A 31-yr-old man with abdominal pain was diagnosed with a pancreatic endocrine tumor 
and multiple hepatic metastases. Despite optimal treatment with interferon alpha, a 
somatostatin analog, local therapy with high-intensity focused ultrasound ablation for 
multiple hepatic metastases, and multiple lines of chemotherapy with etoposide/cisplatin 
combination chemotherapy and gemcitabine monotherapy, the tumor progressed. As few 
chemotherapeutic options were available for him, sorafenib (800 mg/day, daily) was 
administered as a salvage regimen. Sorafenib was continued despite two episodes of grade 
3 skin toxicity; it delayed tumor progression compared to the previous immunotherapy and 
chemotherapy. Serial computed tomography scans showed that the primary and 
metastatic tumors were stable. Thirteen months after beginning targeted therapy, and up 
to the time of this report, the patient is well without disease progression. We suggest that 
sorafenib is effective against pancreatic endocrine tumors.
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Pancreatic endocrine tumors are uncommon, with an annual 
incidence of 1-2 cases/100,000, but their frequency is on the rise 
(1). In younger individuals, hereditary cancer syndromes such 
as multiple endocrine neoplasia type 1 (MEN-1) may contribute 
to these cases. Pancreatic endocrine tumors are classified as func-
tioning or non-functioning based on the presence or absence 
of a clinical symptom. Endocrine tumors of the pancreas are a 
heterogeneous group of neoplasms with natural histories vary-
ing from a frequently indolent course for tumors that are well 
differentiated to a much more aggressive form for poorly differ-
entiated tumors (2). Due to their heterogeneity and rarity, im-
proving the management of these tumors is particularly difficult. 
In general, surgical resection is the procedure of choice for pa-
tients with localized disease or limited metastases (3). In patients 
with advanced disease, clinical trials of immunotherapy and cy-
totoxic chemotherapy have demonstrated the efficacy of sever-
al drugs, including interferon alpha, somatostatin, streptozocin, 
doxorubicin, fluorouracil, dacarbazine, and temozolomide (4).
  To date, however, systemic therapies for endocrine tumors 
have been largely ineffective. Although treatment with soma-
tostatin analogs can usually decrease hormonal symptoms, it 
rarely results in tumor shrinkage. Therefore, although pancre-
atic endocrine tumors are indolent, the prognosis of patients 
with advanced tumors is poor, particularly when the condition 
progresses to a stage at which cytotoxic agents are not effective. 
Presently, drugs targeted to particular molecules involved in en-
docrine tumors are in clinical trials. Herein, we report on a pa-
tient with advanced pancreatic endocrine tumors and liver me-
tastasis who responded favorably to sorafenib after the failure 
of biotherapy and conventional chemotherapy. 
CASE DESCRIPTION
A 31-yr-old man visited our hospital following 10 days of abdom-
inal pain on February 14, 2006. His past history was unremark-
able, as was his family history. His initial computed tomography 
(CT) and positron emission tomography scans showed a 6.8 cm 
lobulated mass in the uncinate process of the pancreas without 
invasion of the adjacent vessels and the common bile duct. The 
tumor showed focal cystic and necrotic areas, and heterogeneous 
enhancement. Multiple hematogenous metastases were also 
noted in the liver (Fig. 1A). Percutaneous needle biopsy of a he-
patic nodule was performed to establish histological diagnosis. 
Atypical cells with an acinar formation were noted but their his-Jeong HK, et al.  •  Pancreatic Endocrine Tumor and Sorafenib 
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tological origin was unknown. Multiple hepatic segmentecto-
my and pancreatic mass resection were performed to confirm 
the histological diagnosis. The tumor cells were arranged in tra-
beculae and solid nests separated by a fibrous or loose fibrovas-
cular stroma. All tumor cells were large and polygonal in shape 
with abundant, eosinophilic, and finely granular cytoplasm. The 
final pathologic examination reported well-differentiated (grade 
2) pancreatic endocrine tumor and metastasis in the liver. This 
was supported by the immunohistochemical study that showed 
the tumor cells were positive for neuron-specific enolase, chro-
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Fig. 1. Radiologic images of pancreatic, non-functioning, well-differentiated, endocrine carcinoma and multiple liver metastases. (A) Contrast enhanced CT scan (02/19/2009) 
shows a 6.8 cm lobulated mass in the uncinated process of the pancreas (arrow). The tumor shows focal cystic and necrotic areas, and heterogeneous enhancement. Multiple 
hematogenous metastases are also noted (arrowheads). (B) Follow-up contrast enhanced CT scan (03/31/2009) shows the lobulated mass in the uncinated process measuring 
5.4 cm in maximal diameter. A comparison with the previous CT scan (A) reveals interval partial regression of the primary tumor mass in the uncinate process (arrow) and he-
matogenous hepatic metastases (arrowheads). 
C
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Fig. 2. Pathologic findings of the pancreatic, non-functioning, well-differentiated, en-
docrine carcinoma. (A) Histologic examination shows that the tumor cells were ar-
ranged in trabeculae and solid nests separated by a fibrous or loose fibrovascular 
stroma (H&E, × 100). (B) All tumor cells were large and polygonal in shape and had 
abundant, eosinophilic, and finely granular cytoplasm containing round to oval nuclei 
with finely stippled chromatin (H&E, × 400). (C) Tumor cells were strongly positive for 
chromogranin (IHC, × 400).Jeong HK, et al.  •  Pancreatic Endocrine Tumor and Sorafenib 
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mogranin, and synaptophysin (Fig. 2). The tumor had 5% Ki-67-
positive cells, and the number of mitoses was 1/10 high-power 
fields. The 24-hr urine 5-hydroxyindoleacetic acid levels were 
10.4 mg/day (normal, < 10 mg/day). The patient had normal 
levels of serum chromogranin A (37.6 ng/mL; normal, 27-94 ng/ 
mL), parathyroid hormone (51.2 pg/mL; normal, 13-60 pg/mL), 
and gastrin (74.5 pg/mL; normal, 0-100 pg/mL).
  Interferon alpha (6 million IU) was administered subcutane-
ously three times a week as first-line therapy. Subsequently, a 
combination etoposide/cisplatin chemotherapy, a somatostatin 
analog (Sandostatin
® LAR, 1 million IU), and gemcitabine mono-
therapy were administered; these therapies, however, failed to 
demonstrate tumor shrinkage or stabilization. Therefore, high-
intensity focused ultrasound ablation (HIFU) with palliative in-
tent was performed for nodules in segments 6 and 8. However, 
2 months after HIFU treatment, the size of the hepatic nodules 
increased. The disease status rapidly deteriorated, but the pa-
tient’s general performance was sufficient to allow considering 
further chemotherapy. We chose sorafenib (800 mg/day, daily) 
as the salvage treatment. DNA from formalin-fixed, paraffin-
embedded primary tumors was used for BRAF mutation analy-
sis. The mutation in exon 15 of the BRAF gene was not found. 
After 3 weeks of sorafenib treatment and two episodes of grade 
3 skin toxicity, the dose was reduced to 600 mg/day. When the 
skin toxicity resolved to less than grade 1, we increased the dose 
of sorafenib to 800 mg/day; the skin toxicity did not increase and 
did not limit the dose. Our patient tolerated sorafenib well. A 
follow-up contrast-enhanced CT scan after 2 months of sorafenib 
therapy revealed that the lobulated mass in the uncinate pro-
cess had become smaller; the maximal diameter was now 5.4 
cm (Fig. 1B). Post-chemotherapy, a contrast-enhanced CT scan 
showed that the target liver lesions had a density of 16 Houn-
sfield units. Thirteen months after beginning sorafenib, no dis-
ease progression was observed and the patient was well. 
DISCUSSION
Pancreatic endocrine tumors account for less than 5% of pan-
creatic cancers (1). They are believed to be derived from amine 
precursor uptake and decarboxylation stem cells and arise from 
cells producing insulin (B cells), glucagon, somatostatin (D cells), 
and pancreatic polypeptide (5). Pancreatic endocrine tumors 
are histologically classified on the basis of tumor cell differenti-
ation as well differentiated endocrine tumors (benign or low-
grade malignancy), well differentiated endocrine carcinomas, 
poorly differentiated endocrine carcinomas (small-cell carcino-
mas), mixed exocrine and endocrine carcinomas (such as ade-
nocarcinoids), and several extremely rare neuroendocrine-like 
lesions (5). Immunohistochemically, these tumors are positive 
for markers of neuroendocrine tissue including neuron-specific 
enolase, chromogranin, and synaptophysin (6). Well differenti-
ated endocrine tumors/carcinomas of the pancreas, as in our 
patient, stain abundantly and diffusely for both chromogranin 
and synaptophysin, whereas poorly differentiated endocrine 
carcinomas stain abundantly and diffusely only for synaptophy-
sin. Pancreatic endocrine tumors are clinically classified as be-
ing functioning or non-functioning. The incidence rate of non-
functioning pancreatic endocrine tumors is between 15% and 
82%; they are pancreatic tumors with endocrine differentiation 
that lack a clinical syndrome of hormone hypersecretion (7, 8). 
Clinical presentation of non-functioning pancreatic endocrine 
tumors is related to the mass effect of the tumor, and symptoms 
resemble those of pancreatic adenocarcinoma; these include 
jaundice, abdominal pain, weight loss, and the appearance of 
an abdominal mass. Radiologically, non-functioning tumors are 
usually manifested as large well-defined masses with moderate 
to strong enhancement without invasion of adjacent vessels (9). 
In our case, the lesion showed a large enhancing pancreatic mass 
with no invasion of adjacent vessels and the common bile duct; 
cystic degeneration of multiple hypervascular metastases was 
observed. These findings were suggestive of non-functioning 
endocrine carcinoma rather than pancreatic adenocarcinoma.
  The median survival time of patients with metastatic pancre-
atic endocrine tumors was only 23 months, but the recent im-
pact of multimodality treatments has prolonged the survival du-
ration to a median of 70 months (8). Poor prognosis is associat-
ed with a high-grade tumor, a high mitotic rate, the presence of 
necrosis, and lymph node and liver metastasis. No difference in 
survival duration exists between patients with functioning and 
non-functioning forms of the tumors (2). Surgical resection is 
considered to be the optimal treatment for localized disease. It 
remains the only curative treatment with a reported 5-yr surviv-
al rate for 75% of cases of non-functioning tumors (10). In pa-
tients with locally advanced and surgically unresectable non-
functioning tumors in the absence of extrapancreatic metastat-
ic disease, the appropriate management remains a difficult ther-
apeutic dilemma due to the indolent natural history; median 
survival is approximately 5 yr. However, more than 70% of pa-
tients with pancreatic endocrine tumors have metastatic disease 
at the initial presentation (7). In these patients, trials of immuno-
therapy and cytotoxic chemotherapy have established the ac-
tivity of several drugs, including interferon alpha, a somatosta-
tin analog, streptozocin, doxorubicin, fluorouracil, dacarbazine, 
temozolomide, and combinations of these modalities. Strepto-
zocin-doxorubicin combination chemotherapy has been con-
sidered the standard of care for patients with metastatic, non-
functioning tumors (4). However, relatively few patients with 
pancreatic endocrine tumors participated in the clinical trials 
due to the low incidence of the disease, the performance status 
of the patients and their previous therapeutic management, and 
the heterogeneity and stage of progression of their tumors. More-
over, retrospective studies have raised questions about the value Jeong HK, et al.  •  Pancreatic Endocrine Tumor and Sorafenib 
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of streptozocin-based chemotherapy because of a low response 
rate (11). Hence, more effective and less toxic therapies are clear-
ly needed for metastatic pancreatic endocrine tumors.
  The molecular pathogenesis of endocrine tumors of the di-
gestive tract is largely unknown and does not involve mutations 
in classical oncogenes such as Ras, Myc, Fos, and Jun, or tumor 
suppressors like p53 and the retinoblastoma susceptibility gene. 
Recent investigations of neuroendocrine tumors have indeed 
shown attractive potential molecular targets such as epidermal 
growth factor receptor (EGFR) (12), vascular endothelial growth 
factor (VEGF) and its receptor (VEGFR) (13), insulin-like growth 
factor receptor (IGFR) (14), and mammalian target of rapamy-
cin (mTOR) pathway kinases (15). These findings suggest a role 
for molecular targeted agents in treatment of these tumors, and 
several targeted agents directed against neuroendocrine tumors 
are currently in clinical trials. In a phase II trial of imatinib ther-
apy for carcinoid tumors, Carr et al. (16) reported that only one 
of 27 patients achieved an objective response, but a significant 
number of patients with progressive disease achieved stabiliza-
tion and an encouraging median progression-free survival du-
ration of 24 weeks. In a phase II study to evaluate the efficacy 
and safety of sunitinib, the overall objective response rate in pa-
tients with unresectable neuroendocrine tumors was 16.7% (11 
of 66 patients), and 68% (45 of 66 patients) had stable disease 
(17). Everolimus, an inhibitor of mTOR, showed an overall ob-
jective response rate of 9.6% in 115 patients with carcinoids or 
islet cell tumors in a phase II trial (18).
  The mitogen-activated protein kinase (MAPK) pathway is piv-
otal for the regulation of proliferation and protection from apop-
tosis in many cell types. In endocrine and melanoma cells, MAPK 
is activated by the Raf kinases B-Raf and Raf-1, which are in turn 
stimulated by small G-protein Rap1. B-Raf is highly expressed 
and has been shown to be the main activator of MAPK signaling 
in neuroendocrine cells (19). These findings imply a possible 
role for targeted agents against B-Raf for the treatment of pan-
creatic endocrine tumors. However, no published clinical data 
exist on the use of a B-Raf inhibitor as therapy for patients with 
these tumors. The orally administered targeted-agent sorafenib 
(Nexavar
®, Bayer Pharmaceuticals Corporation, West Haven, 
CT, USA) was approved for patients with advanced renal cell car-
cinoma and hepatocellular carcinoma. It inhibits tumor-cell pro-
liferation and tumor angiogenesis, and increases the rate of apop-
tosis in a wide range of tumor models. It acts by inhibiting the 
RAF serine/threonine kinases (RAF-1, wild-type BRAF, V600E 
BRAF), the receptor tyrosine kinase activity of VEGFRs 1, 2, and 
3, and platelet-derived growth factor receptor β (PDGFR-β). A 
study by Wilhelm et al. (20) demonstrated that sorafenib inhib-
ited the MAPK pathway in neuroendocrine cell lines; MAPK ac-
tivation and proliferation were inhibited by high concentrations 
of sorafenib. Nonspecific effects of sorafenib such as the inhibi-
tion of the tyrosine kinase receptors of VEGFR, PDGFR-β, and 
c-KIT may have the potential to increase the effect of specific 
Raf kinase inhibition in a clinical setting. The efficacy of sorafenib 
was also observed in wild-type and mutant BRAF. 
  The present patient had an advanced pancreatic endocrine 
tumor and his clinical features suggested a poor outcome. The 
tumor was progressing and showed no response to biotherapy 
and conventional cytotoxic chemotherapy. We used sorafenib 
as a salvage alternative. The overall response to sorafenib was 
stable. Since beginning targeted therapy and up to the time of 
this report, the patient has received sorafenib and remains well 
without progression of disease. Stabilization of disease without 
tumor shrinkage may represent a meaningful benefit and has 
become an important issue since the introduction of molecular 
targeted agents in clinical trials. 
  In conclusion, this is the first case report indicating that sora-
fenib may be effective against pancreatic endocrine tumors. 
Further clinical studies are needed to explore sorafenib efficacy 
in the treatment of these tumors. 
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